#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15206	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2169	698.2	0	.	n	.	0	A69G	SNP	69	69	A	347	347	G	832	G,T	775,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15206	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2169	698.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1728	1728	T	830	T,C	765,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15206	16S	1529	1529	99.87	16S.l6.c4.ctg.1	2169	698.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1462	1462	C	884	C	820	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28460	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3578	793.0	0	.	n	.	0	T695C	SNP	695	695	T	1114	1114	C	874	C	808	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28460	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3578	793.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2390	2390	C	899	C	835	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28460	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3578	793.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2464	2464	A	930	A	871	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28460	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3578	793.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	3016	3016	C	836	C	783	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2206	folP	855	855	100.0	folP.l15.c4.ctg.1	1631	134.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1037	1039	AGC	219;222;221	A;G;C	206;208;205	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5980	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3249	182.8	1	SNP	p	S91F	1	.	.	271	273	TTC	548	550	TTC	195;196;198	T;T;C	185;186;187	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5980	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3249	182.8	1	SNP	p	G95N	0	.	.	283	285	GGC	560	562	GGC	189;192;195	G;G;C	177;179;176	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5980	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3249	182.8	1	SNP	p	D95G	1	.	.	283	285	GGC	560	562	GGC	189;192;195	G;G;C	177;179;176	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1854	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1290	142.9	0	.	p	.	0	D79N	NONSYN	235	237	GAT	591	593	AAT	242;241;244	A;A;T	228;227;230	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	1854	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1290	142.9	1	SNP	p	G45D	0	.	.	133	135	GGC	489	491	GGC	238;236;236	G;G;C	222;220;219	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	850	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1064	79.8	0	.	n	.	0	A197.	DEL	197	197	A	635	635	A	177	A	168	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5268	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2903	180.6	0	.	p	.	0	E91G	NONSYN	271	273	GAG	549	551	GGG	186;191;192	G;G,A;G	177;181,1;182	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5268	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2903	180.6	1	SNP	p	D86N	0	.	.	256	258	GAC	534	536	GAC	180;180;181	G;A;C	169;165;172	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5268	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2903	180.6	1	SNP	p	S87R	0	.	.	259	261	AGT	537	539	AGT	185;184;185	A,C;G;T	174,1;174;172	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5268	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2903	180.6	1	SNP	p	S87I	0	.	.	259	261	AGT	537	539	AGT	185;184;185	A,C;G;T	174,1;174;172	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5268	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2903	180.6	1	SNP	p	S87W	0	.	.	259	261	AGT	537	539	AGT	185;184;185	A,C;G;T	174,1;174;172	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5268	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2903	180.6	1	SNP	p	S88P	0	.	.	262	264	TCC	540	542	TCC	182;181;185	T;C;C	171;173;175	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4930	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2680	183.5	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1627	1629	CAC	223;222;220	C;A;C	201;201;198	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4930	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2680	183.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1576	1578	GGC	242;243;244	G;G;C,T	226;225;223,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1210	1212	GCA	250;249;247	G;C;A	229;225;226	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1213	1215	ATC	250;250;250	A;T;C	228;227;227	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1225	1227	GTG	253;249;252	G;T;G,T	228;221;228,1	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1225	1227	GTG	253;249;252	G;T;G,T	228;221;228,1	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1729	1731	ACC	219;220;216	A,G;C;C	191,1;197;196	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1783	1785	ACG	215;216;216	A,G;C;G	177,1;187;186	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1783	1785	ACG	215;216;216	A,G;C;G	177,1;187;186	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1906	1908	GGC	203;200;199	G;G;C	188;188;186	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1915	1917	GGC	195;195;191	G;G;C	182;180;178	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4290	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2298	185.8	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1933	1935	CTG	177;182;181	C,G;T;G	137,8;131;140	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6148	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3132	195.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1738	1740	CCG	222;226;218	C;C;G	200;209;197	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2438	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1761	137.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	544	544	C	175	C	153	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	0	.	p	.	0	T26A	NONSYN	76	78	ACC	368	370	GCC	220;222;226	G;C;C	205;205;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	0	.	p	.	0	N38E	NONSYN	112	114	AAT	404	406	GAA	223;224;225	G;A;A	212;213;213	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	0	.	p	.	0	N124S	NONSYN	370	372	AAT	662	664	AGT	234;232;230	A;G;T	216;214;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	0	.	p	.	0	P175S	NONSYN	523	525	CCA	815	817	TCA	240;242;240	T;C;A	224;227;228	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	0	.	p	.	0	A218V	NONSYN	652	654	GCC	944	946	GTC	259;254;253	G,C;T;C	240,1;239;238	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	0	.	p	.	0	F222S	NONSYN	664	666	TTT	956	958	TCT	257;254;254	T;C;T	241;240;240	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1274	1276	GCA	235;235;235	G;C;A	216;214;216	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	1	SNP	p	G120K	1	.	.	358	360	AAG	650	652	AAG	237;235;236	A;A;G	218;219;219	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	1	SNP	p	A121D	1	.	.	361	363	GAC	653	655	GAC	238;236;237	G;A;C	220;220;221	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2910	porB1b	1047	1047	99.14	porB1b.l15.c4.ctg.1	1703	170.3	1	SNP	p	D121N	0	.	.	361	363	GAC	653	655	GAC	238;236;237	G;A;C	220;220;221	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11060	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4756	231.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1942	1944	CAT	248;248;246	C;A;T	227;226;223	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1126	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1084	103.4	1	SNP	p	V57M	1	.	.	169	171	ATG	580	582	ATG	232;231;230	A;T,C;G	216;215,1;214	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
